Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by ...

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New ...

Geopolitical friction hasn’t slowed outbound moves as Keeta enters Brazil, Huawei bets on ASEAN energy, and robotaxis roll ...

GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion ...

This drugmaker achieved a milestone - its first quarterly profit. But the stock is down despite the good tidings.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Qatar pushes back on reports of $400M Boeing jet gift to Trump These Frozen Appetizers At Costco Are Better Than Restaurant Made House GOP tax bill calls for ‘SALT’ deduction cap of $30,000 ...

Serial CTRS (CT Response Score) improves prediction of overall survival compared to RECIST 1.1 and Tumor Volume Change in advanced NSCLC CHICAGO--(BUSINESS WIRE)--Onc.AI, a digital health company ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on BeiGene (ONC – Research Report), with a price target of $334.00. The company’s shares closed yesterday at $249.13.